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As the 2020 target for LF elimination looms, we are still far from reaching this goal. This 
must not be considered as a failure of the programme, but instead as failure to set realistic 
and achievable targets.  
Now, findings on household-level productivity loss among people with LF – and for other 
neglected diseases - are most important for themselves and their household members and 
for the world to know.  Of all the evidence for rational policy making that is needed, 
economic evidence is often politically most interesting to policy makers at the global and 
local levels: they justify continuing and increased investments.  
New approaches to deal with transmission hotspots, cross-border endemicity, conflicts and 
environmental catastrophes and integration of vertical programmes into fragile systems 
require continued research and further investments in programme implementation to meet 
elimination objectives. And now, let us learn from our past and present experiences and 
trash the targets. 
Globally, lymphatic filariasis (LF) remains an immense problem for the affected individuals 
and communities both in terms of health and wellbeing, as well as in economic measures.[1, 
2] It is a parasitic disease and an important cause of chronic morbidity in low-income 
countries[3]. The internationally supported strategy is to break disease transmission by 
mass treatment of affected communities with antifilarial drugs and provision of morbidity 
management and disability prevention for patients with clinical disease (lymphoedema and 
hydrocoele). [3] Current drugs, all of which are wholly or partially donated by pharma 
companies, are diethylcarbamazine or ivermectin, combined with albendazole, which 
predominantly kill the microfilariae i.e. the parasites offspring.  
As the 2020 target for LF elimination looms, we are still far from reaching this goal. This 
must not be seen as a failure of the programme, but instead a failure to set a realistic and 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz674/5538392 by U
niversity of Liverpool user on 06 August 2019
 
 
achievable target. Setting targets is a politically precarious exercise, which risks 
compromising continued donor support, investment in continued R&D and the credibility of 
health policy makers in this domain. The arguments for setting targets are often generic, 
poorly justified, and only driven by international bodies, yet fail to consider valuable lessons 
from previous experiences of premature targets. Why not simply make the target - the 
elimination of LF? This 2020 milestone, nevertheless, has driven reviews of the immense 
health and economic burden of LF to justify continued investment at global and national 
levels towards the elimination of this disabling disease. 
Mathew et al. present in this issue detailed estimates of the global health and economic 
burden of LF, prior to the start of mass drug administration (MDA) programmes in 2000.[2] 
They conclude that, despite considerable progress in reaching the vulnerable, poor and 
often hard-to-reach populations, there is still a huge task for national governments and the 
supporting international agencies to secure increased prevention, treatment, and financing 
options for the near future.  
     The authors estimated the global burden of LF before the introduction of MDA in a 
careful and transparent way. Worldwide it is a big societal burden: about 130 million people 
were affected with a third suffering from clinical manifestations. The findings on the average 
annual economic burden per household are new: these amount to a US$115 per chronic 
case, with the major part coming from productivity loss and subsequent lost income at the 
household level. The total global economic burden of LF in the pre-MDA situation was 
estimated at US$5.8 billion annually.  The productivity losses are from both the acute and 
chronic – lifetime consequences of LF.   
   The total estimates of productivity are, however, measured in several ways and vary from 
US$1.5 billion to US$13.2 billion, depending on the selected economic approach. The 
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authors use existing methods and documented modeling approaches published already with 
comparative results yet over different time intervals since implementing MDA programmes 
for LF[4]. Uncertainties are a consequence of the paucity of robust data across the globe and 
are, hence, inevitable, yet are well described. Redekop and Lenk et al. also published 
estimates, based on similar data and methods, also applied to other NTDs, and arrive at 
corresponding findings. [5] 
  The Global Programme to Eliminate Lymphatic Filariasis (GPELF), launched in 2000, aims to 
eliminate LF as a public health problem by 2020. The present coverage of MDA programmes 
is only 40%, while the 2013 WHO estimates from the global disease burden programme 
report an observed decline in DALYs of only about 30% since 1990. With this limited decline 
over the past two decades, the situation urges for continuous and increased investments in 
MDA, as well as for an additional and much stronger focus on the management of long-term 
morbidity and disability, given the international commitment to universal health coverage 
and financial protection especially in case of chronic diseases. [6, 7].  
 
   The new findings on household-level productivity loss among people with LF – and for 
other neglected diseases - are most important for themselves and their household members 
and for the world to know.  There is still a major omission: the mental health burden in 
terms of depression among chronic disease patients and their carers, because of stigma and 
disability is documented to be at least half of the primary LF burden.[8, 9] Of all the 
evidence for rational policy making that is needed, economic evidence is often politically the 
most interesting to policy makers at the global, national, and local level, as they do justify 
continuing and increased investments across disease control programmes. It is clear in the 
case of LF, that the potential societal returns of investments are huge. This research serves 
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an immediate and direct purpose i.e. global advocacy in relation to priority setting as 
already seen in various other disease control areas, demonstrating its net worth to societies. 
[5, 10, 11].  
 
A better understanding of the existing barriers to the integration and scaling-up of 
Neglected Tropical Disease programmes requires ongoing multi-disciplinary implementation 
research. Improvements in alternative treatment strategies  [12]; combination regimens of 
existing drugs [13] and the benefits of complementary vector control  [14] require large-
scale multi-disciplinary evaluation and integration into existing strategies in order to bring 
about the benefits of reducing the challenging programmatic timeframes. New approaches 
to deal with transmission hotspots, cross-border endemicity, the risk of conflict and 
environmental catastrophe and integration of vertical programmes into fragile health 
systems also requires continued research and further investments in programme 
implementation to meet the elimination objectives.  
 
And now, let us learn from this and previous experiences and trash the targets. 
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